(NASDAQ: LYEL) Lyell Immunopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.03%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.07%.
Lyell Immunopharma's earnings in 2026 is -$248,477,000.On average, 10 Wall Street analysts forecast LYEL's earnings for 2026 to be -$190,931,806, with the lowest LYEL earnings forecast at -$207,009,629, and the highest LYEL earnings forecast at -$176,767,835. On average, 10 Wall Street analysts forecast LYEL's earnings for 2027 to be -$196,430,760, with the lowest LYEL earnings forecast at -$235,587,525, and the highest LYEL earnings forecast at -$133,026,158.
In 2028, LYEL is forecast to generate -$166,411,962 in earnings, with the lowest earnings forecast at -$212,773,238 and the highest earnings forecast at -$138,456,497.